

Concizumab may be effective prophylaxis for hemophilia A or B with inhibitors

September 3 2023, by Lori Solomon



Patients with hemophilia A or B with inhibitors have a lower annualized

bleeding rate with concizumab than with no prophylaxis, according to a phase 3 study published online Aug. 31 in the *New England Journal of Medicine*.

Tadashi Matsushita, M.D., Ph.D., from Nagoya University Hospital in Japan, and colleagues evaluated the safety and efficacy of concizumab in [patients](#) with [hemophilia](#) A or B with inhibitors. As part of the exploratory phase 3 trial, participants were randomly assigned to receive no [prophylaxis](#) for at least 24 weeks (group 1; 19 patients) or to receive concizumab prophylaxis for at least 32 weeks (group 2; 33 patients), or they were nonrandomly assigned to receive concizumab prophylaxis for at least 24 weeks (groups 3 and 4; 81 patients).

The researchers found that the estimated mean annualized bleeding rate in group 1 was 11.8 episodes versus 1.7 episodes in group 2 (rate ratio, 0.14; P

"Concizumab represents a novel, subcutaneous treatment option in patients with hemophilia A or B with inhibitors that can potentially improve long-term outcomes," the authors write.

More information: Tadashi Matsushita et al, Phase 3 Trial of Concizumab in Hemophilia with Inhibitors, *New England Journal of Medicine* (2023). [DOI: 10.1056/NEJMoa2216455](https://doi.org/10.1056/NEJMoa2216455)

H. Marijke van den Berg et al, Hemostasis—A Balancing Act, *New England Journal of Medicine* (2023). [DOI: 10.1056/NEJMe2304535](https://doi.org/10.1056/NEJMe2304535)

Copyright © 2023 [HealthDay](#). All rights reserved.

Citation: Concizumab may be effective prophylaxis for hemophilia A or B with inhibitors (2023, September 3) retrieved 30 April 2024 from

<https://medicalxpress.com/news/2023-09-concizumab-effective-prophylaxis-hemophilia-inhibitors.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.